Ignite Creation Date:
2025-12-18 @ 9:34 AM
Ignite Modification Date:
2025-12-18 @ 9:34 AM
Study NCT ID:
NCT00942578
Status:
None
Last Update Posted:
2018-10-11 00:00:00
First Post:
2009-07-18 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
Sponsor:
None
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-07-16
Start Date Type:
ACTUAL
Primary Completion Date:
2017-07-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-07-31
Completion Date Type:
ACTUAL
First Submit Date:
2009-07-18 00:00:00
First Submit QC Date:
None
Study First Post Date:
2009-07-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-07-25 00:00:00
Results First Submit QC Date:
None
Results First Post Date:
2018-10-11
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-09-11 00:00:00
Last Update Post Date:
2018-10-11 00:00:00
Last Update Post Date Type:
ACTUAL